Literature DB >> 19636216

Adiponectin is related to intramyocellular lipid content in non-diabetic adults.

A F Godoy-Matos1, L R Bahia, R C Domingues, F Sicuro, M Tambascia, B Geloneze, L G Kraemer-Aguiar, E Bouskela.   

Abstract

OBJECTIVE: Insulin resistance (IR) is associated with intramyocellular lipid (IMCL) content and low serum adiponectin (ADP) levels and ADP is also involved in muscle fat oxidation. However, the relationship between ADP and IMCL content is still controversial and in this study we explored it further in non-diabetic adults.
DESIGN: Cross-sectional clinical study.
SUBJECTS: Thirty-three adult subjects, 24 obese non-diabetic patients with metabolic syndrome (MS) and 9 lean healthy controls. MEASUREMENTS: Proton nuclear magnetic resonance spectroscopy (1H-NMRS) was performed to quantify IMCL content. The latter plus serum ADP, anthropometrics and biochemical parameters were evaluated and compared in these 2 groups.
RESULTS: MS patients had higher body mass index, waist, waist-to- hip ratio, glucose, insulin, and triglycerides and lower HDL cholesterol (HDLc) compared to controls. Homeostasis model assessment of IR (HOMA-IR) [3.25 (2.58-4.13) vs 1.02 (0.73- 1.29); p<0.0001] and IMCL content [266.1 (189.9-296.3) vs 72.85 (55.3-109.4) AU, p<0.0001] were higher, and quantitative insulin-sensitivity check index (QUICKI) [0.32 (0.31-0.33) vs 0.38 (0.37-0.40); p<0.0001] and ADP [8.6 (4.05-15.95) vs 21.1 (12.9- 24.4) microg/ml; p=0.02] were lower in MS subjects compared to controls. IMCL content was directly associated to glucose, insulin, triglycerides, and HOMA-IR and inversely to HDLc, QUICKI and, more importantly, to ADP (r=-0.41; p<0.05). Only in the MS group, ADP partially influenced IMCL content.
CONCLUSION: ADP is inversely related to IMCL content in non-diabetic adults. This finding has possible implications for the role of ADP in muscle fat oxidation, IR, and MS.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19636216     DOI: 10.1007/BF03346608

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  32 in total

1.  Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report.

Authors: 
Journal:  Circulation       Date:  2002-12-17       Impact factor: 29.690

Review 2.  Role of the adipocyte, free fatty acids, and ectopic fat in pathogenesis of type 2 diabetes mellitus: peroxisomal proliferator-activated receptor agonists provide a rational therapeutic approach.

Authors:  Harold Bays; Lawrence Mandarino; Ralph A DeFronzo
Journal:  J Clin Endocrinol Metab       Date:  2004-02       Impact factor: 5.958

3.  Role of adiponectin in human skeletal muscle bioenergetics.

Authors:  Anthony E Civitarese; Barbara Ukropcova; Stacy Carling; Matthew Hulver; Ralph A DeFronzo; Lawrence Mandarino; Eric Ravussin; Steve R Smith
Journal:  Cell Metab       Date:  2006-07       Impact factor: 27.287

Review 4.  Failure of fat cell proliferation, mitochondrial function and fat oxidation results in ectopic fat storage, insulin resistance and type II diabetes mellitus.

Authors:  L Heilbronn; S R Smith; E Ravussin
Journal:  Int J Obes Relat Metab Disord       Date:  2004-12

5.  Adiponectinemia in visceral obesity: impact on glucose tolerance and plasma lipoprotein and lipid levels in men.

Authors:  Mélanie Côté; Pascale Mauriège; Jean Bergeron; Natalie Alméras; Angelo Tremblay; Isabelle Lemieux; Jean-Pierre Després
Journal:  J Clin Endocrinol Metab       Date:  2004-12-14       Impact factor: 5.958

6.  The relationships of plasma adiponectin with a favorable lipid profile, decreased inflammation, and less ectopic fat accumulation depend on adiposity.

Authors:  Konstantinos Kantartzis; Killian Rittig; Bernd Balletshofer; Jürgen Machann; Fritz Schick; Katarina Porubska; Andreas Fritsche; Hans-Ulrich Häring; Norbert Stefan
Journal:  Clin Chem       Date:  2006-08-17       Impact factor: 8.327

7.  Association of increased intramyocellular lipid content with insulin resistance in lean nondiabetic offspring of type 2 diabetic subjects.

Authors:  S Jacob; J Machann; K Rett; K Brechtel; A Volk; W Renn; E Maerker; S Matthaei; F Schick; C D Claussen; H U Häring
Journal:  Diabetes       Date:  1999-05       Impact factor: 9.461

8.  Tissue specificity of insulin resistance in humans: fat in the liver rather than muscle is associated with features of the metabolic syndrome.

Authors:  A Kotronen; A Seppälä-Lindroos; R Bergholm; H Yki-Järvinen
Journal:  Diabetologia       Date:  2007-11-16       Impact factor: 10.122

9.  Decreased plasma adiponectin concentrations in women with dyslipidemia.

Authors:  Miyao Matsubara; Shoji Maruoka; Shinji Katayose
Journal:  J Clin Endocrinol Metab       Date:  2002-06       Impact factor: 5.958

10.  Body composition, visceral fat, leptin, and insulin resistance in Asian Indian men.

Authors:  M A Banerji; N Faridi; R Atluri; R L Chaiken; H E Lebovitz
Journal:  J Clin Endocrinol Metab       Date:  1999-01       Impact factor: 5.958

View more
  3 in total

Review 1.  Epidemiology of myosteatosis.

Authors:  Iva Miljkovic; Joseph M Zmuda
Journal:  Curr Opin Clin Nutr Metab Care       Date:  2010-05       Impact factor: 4.294

2.  Adiponectin is inversely associated with intramyocellular and intrahepatic lipids in obese premenopausal women.

Authors:  Miriam A Bredella; Martin Torriani; Reza H Ghomi; Bijoy J Thomas; Danielle J Brick; Anu V Gerweck; Lindsey M Harrington; Karen K Miller
Journal:  Obesity (Silver Spring)       Date:  2010-12-09       Impact factor: 5.002

3.  Polymorphism in LEP and LEPR May Modify Leptin Levels and Represent Risk Factors for Thyroid Cancer.

Authors:  Marjory Alana Marcello; Antonio Ramos Calixto; Jacqueline Fatima Martins de Almeida; Mariana Bonjiorno Martins; Lucas Leite Cunha; Camila Ayume Amano Cavalari; Elba C S Etchebehere; Ligia Vera Montalli da Assumpção; Bruno Geloneze; Andre Lopes Carvalho; Laura Sterian Ward
Journal:  Int J Endocrinol       Date:  2015-02-25       Impact factor: 3.257

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.